UCB S.A.: all 580 studies

Page 4 of 6. Open to participants first (26), then studies with results posted, then the rest; newest registration first within each.

• Certolizumab Pegol for Treatment of Adult Greek Patients With Moderate to Severe Crohn's Disease Who Failed InfliximabTerminatedNCT00307931Phase 3Results posted
• Mucosal Healing Study in Crohn's Disease (CD)CompletedNCT00297648Phase 3Results posted
• Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson SymptomsCompletedNCT00296192Phase 2Results posted
• Compare the Efficacy of Levocetirizine and Montelukast to Placebo in Reducing Seasonal Allergic Rhinitis (SAR) Symptoms in Ragweed Sensitive SubjectsCompletedNCT00295022Phase 4Results posted
• Cardiac Effects of Rotigotine Transdermal System in Subjects With Advanced-stage Idiopathic Parkinson's DiseaseCompletedNCT00292227Phase 1Results posted
• Clinical Study of CDP870/Certolizumab Pegol in Patients With Active Crohn's DiseaseCompletedNCT00291668Phase 2Results posted
• Follow up Trial for Keppra (Levetiracetam) as Monotherapy in Patients With Newly Diagnosed Epilepsy Coming From N01175 (NCT00175903).CompletedNCT00291655Phase 3Results posted
• A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis (SAR) in Sensitive Subjects Exposed to Ragweed PollenCompletedNCT00291642Phase 2Results posted
• Trial to Compare Time to Response in the Symptoms of Anxiety to Concomitant Treatment With Niravam™ and an SSRI or SNRI to Treatment With an SSRI or SNRI Alone in Subjects With Generalized Anxiety Disorder or Panic DisorderCompletedNCT00266409Phase 4Results posted
• CUTE (Chronic Urticaria Treatment Evaluation)CompletedNCT00264303Phase 4Results posted
• Efficacy Study of CDP870 in Subjects With Chronic Plaque Psoriasis Who Are Candidate for Systemic Therapy and/or Phototherapy/PhotochemotherapyCompletedNCT00245765Phase 2Results posted
• An Open-label Continuation Trial to Assess the Continued Efficacy and Safety of Ascending Doses of Lacosamide in Subjects With Chronic Refractory Neuropathic PainCompletedNCT00237458Phase 2Results posted
• A Follow-On Trial to Assess the Long Term Safety and Efficacy of SPM 927 in Painful Distal Diabetic NeuropathyCompletedNCT00235443Phase 2/3Results posted
• A Trial to Assess the Long-term Safety and Efficacy of Lacosamide in Subjects With Painful Diabetic NeuropathyCompletedNCT00220337Phase 3Results posted
• Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From EpilepsyCompletedNCT00175916Phase 3Results posted
• A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00175877Phase 3Results posted
• A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.CompletedNCT00175825Phase 2Results posted
• A follow-on Safety Study in Subjects With Crohn's Disease Who Have Previously Been Withdrawn From the Double-blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Due to an Exacerbation of Crohn's DiseaseCompletedNCT00160706Phase 3Results posted
• Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid ArthritisCompletedNCT00160693Phase 3Results posted
• ATAREAL (Antihistamine Treatment for Allergic Rhinitis in Real Life)CompletedNCT00160680Phase 4Results posted
• A Study Assessing Efficacy of Brivaracetam in Subjects With Persistent Pain After Shingles (Post-herpetic Neuralgia)CompletedNCT00160667Phase 2Results posted
• Open Label Safety and Efficacy Study of Levetiracetam in Patients With EpilepsyCompletedNCT00160654Phase 4Results posted
• A Study of the Safety and Effectiveness of Liquid Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid ArthritisCompletedNCT00160641Phase 3Results posted
• Follow-up Study of L059 (Levetiracetam) in Epileptic Patients With Partial Onset Seizures by Open Label MethodCompletedNCT00160615Phase 3Results posted
• Prevention of Asthma With Levocetirizine (36 Month Treatment) in Young Children Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and House Dust Mite and Having Completed the Previous EPAAC Trial (NCT00152464)TerminatedNCT00160563Phase 3Results posted
• A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]CompletedNCT00160524Phase 3Results posted
• Long-Term, Follow-Up Study Of the Safety And Efficacy Of Levetiracetam In Children With Partial Onset SeizuresCompletedNCT00152516Phase 3Results posted
• Study With Subjects 18-65 Years Old With Partial Onset Seizures Who Are Currently Taking LevetiracetamCompletedNCT00152503Phase 2Results posted
• A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung CancerCompletedNCT00152477Phase 2Results posted
• Prevention of Asthma With Levocetirizine 18 Month Treatment in Infants (12 - 24 Months) Suffering From Eczema (Atopic Dermatitis) and Sensitized to Grass Pollen and/or House Dust Mite (HDM)CompletedNCT00152464Phase 3Results posted
• Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset SeizuresCompletedNCT00152451Phase 2Results posted
• Monotherapy With Levetiracetam in Patients Suffering From Epilepsy.CompletedNCT00150813Phase 3Results posted
• This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam TreatmentCompletedNCT00150800Phase 3Results posted
• A Study Of The Safety And Efficacy Of Levetiracetam (Keppra®) (Ucb L059) In Children With EpilepsyCompletedNCT00150709Phase 3Results posted
• A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of UCB0159 in Participants With Mild to Moderate Psoriasis, Single Dose Pharmacokinetics and Safety in Healthy Participants.CompletedNCT07849894Phase 1
• A Phase 1 Study of Cizutamig in IgE Mediated DiseasesWithdrawnNCT07408869Phase 1
• A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of UCB5285 in Healthy Study ParticipantsActive, not recruitingNCT07286682Phase 1
• A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic DermatitisActive, not recruitingNCT07277660Phase 2
• Absolute Bioavailability Study of Cizutamig in Healthy Adult ParticipantsCompletedNCT07236411Phase 1
• A Phase 1 Relative Bioavailability Study of UCB0022 Tablets in Healthy ParticipantsCompletedNCT07220551Phase 1
• An Open-label Study of CND261 in Seropositive Rheumatoid ArthritisActive, not recruitingNCT07052032Phase 1
• A Study to Assess the Time to Onset of Action of Staccato Alprazolam Versus Midazolam and Diazepam in Healthy ParticipantsCompletedNCT07020988Phase 1
• A Study to Assess the Safety and Tolerability, and Pharmacokinetics of UCB0022 in Healthy Caucasian, Japanese, and Chinese ParticipantsCompletedNCT06970301Phase 1
• A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis SuppurativaActive, not recruitingNCT06921850Phase 3
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese ParticipantsCompletedNCT06716879Phase 1
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic ArthritisCompletedNCT06624228Phase 3
• A First-in-human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB3101 in Healthy ParticipantsTerminatedNCT06555601Phase 1
• An Extension Study Evaluating 6-week Treatment Cycles of Rozanolixizumab in Pediatric Study Participants With Generalized Myasthenia GravisActive, not recruitingNCT06540144Phase 3
• A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06506916Phase 3
• A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT06425549Phase 3
• A Study to Assess the Safety and Pharmacokinetics of a Single Dose of UCB9741 in Healthy Caucasian and Japanese ParticipantsCompletedNCT06315335Phase 1
• A Study to Test the Long-term Safety and Tolerability of Brivaracetam in Study Participants With Childhood Absence Epilepsy or Juvenile Absence EpilepsyActive, not recruitingNCT06315322Phase 3
• A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Severe Generalized Myasthenia GravisCompletedNCT06149559Phase 2/3
• A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet SyndromeCompletedNCT06118255Phase 3
• A Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of UCB0022 in Study Participants With Advanced Parkinson's DiseaseCompletedNCT06055985Phase 2
• A Relative Bioavailability Study of Staccato Alprazolam Versus Oral Alprazolam in Healthy Study ParticipantsCompletedNCT05626439Phase 1
• A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)CompletedNCT05277571Phase 1/2
• A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.Active, not recruitingNCT05064878Phase 3
• A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)Active, not recruitingNCT05063162Phase 3
• A Study to Evaluate the Relative Bioavailability and Tolerability of Bimekizumab in Healthy SubjectsCompletedNCT05028127Phase 1
• A Retrospective Study of Subjects With Thymidine Kinase 2 DeficiencyCompletedNCT05017818
• CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)No longer availableNCT05014724
• A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis SuppurativaCompletedNCT04901195Phase 3
• A Study to Test the Safety, Tolerability, and Pharmacokinetics of UCB0599 in Healthy Study Participants and Patients With Parkinson's Disease (PD)CompletedNCT04875962Phase 1
• A Study to Test the Safety, Tolerability, and Blood Levels of UCB0022 in Healthy Participants and Participants With Parkinson's DiseaseCompletedNCT04867642Phase 1
• A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD)CompletedNCT04867616Phase 2
• A Study to Assess the Pharmacokinetics (PK) and Safety of Staccato Alprazolam in Adolescent Study Participants With EpilepsyCompletedNCT04857307Phase 1
• A Study to Assess the Pulmonary Safety of Staccato Alprazolam in Healthy Study Participants and in Study Participants With Mild AsthmaCompletedNCT04802746Phase 1
• Study to Assess the Safety, Tolerability, And Pharmacokinetics of Staccato Alprazolam in Healthy Japanese, Chinese, and Caucasian ParticipantsCompletedNCT04782388Phase 1
• A Study to Test Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Intravenous Doses of Zampilimab in Healthy ParticipantsCompletedNCT04705350Phase 1
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of Age With Childhood Absence Epilepsy or Juvenile Absence EpilepsyCompletedNCT04666610Phase 3
• A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear PalsyActive, not recruitingNCT04658199Phase 1
• A Safety and Pharmacokinetics Study of UCB7853 in Healthy Study Participants and Study Participants With Parkinson's Disease (PD)CompletedNCT04651153Phase 1
• A Study to Test Efficacy, Safety, and Pharmacokinetics of Certolizumab Pegol in Children and Adolescents With Moderately to Severely Active Crohn's DiseaseWithdrawnNCT04643483Phase 3
• A Study to Test the Safety, Pharmacokinetics, and Efficacy of UCB9741 in Healthy Study Participants and in Study Participants With Atopic DermatitisCompletedNCT04643457Phase 1/2
• A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)WithdrawnNCT04581733Phase 3
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UCB8600 in Healthy Participants, Atopic Participants, and Chronic Spontaneous Urticaria ParticipantsTerminatedNCT04444466Phase 1
• A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial SpondyloarthritisCompletedNCT04436640Phase 3
• European Non-interventional Study on Refractory Epilepsy With Developmental DelayTerminatedNCT04398667
• A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Zampilimab in Adult Kidney Transplant Recipients With Chronic Allograft InjuryTerminatedNCT04335578Phase 1/2
• A Study to Test the Blood Concentration of 4 Padsevonil Product Variants and the Effect of Food on PadsevonilWithdrawnNCT04283136Phase 1
• Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisCompletedNCT04225871Phase 3
• A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)CompletedNCT04185415Phase 1
• A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT04123795Phase 3
• A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical PracticeCompletedNCT04053881
• A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisCompletedNCT04009499Phase 3
• A Study to Evaluate the Antibody Response of Influenza Vaccination Following Concomitant Exposure to Bimekizumab in Healthy SubjectsCompletedNCT03895385Phase 1
• A Study to Evaluate Safety and Tolerability of Single Ascending Doses of Rozanolixizumab Administered by Subcutaneous Infusion in Healthy Japanese, Chinese and Caucasian Study ParticipantsCompletedNCT03859219Phase 1
• An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 DeficiencyCompletedNCT03845712Phase 2
• ZX008 Expanded Access ProtocolApproved for marketingNCT03780127
• A Study to Compare the Blood Level of Bimekizumab Injected Subcutaneously Either by a Prefilled Syringe or by an Auto-injector in Adult Healthy Volunteer ParticipantsCompletedNCT03707717Phase 1
• A RETROspective Study of Patients With TK2dCompletedNCT03701568
• A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary GeneralizationCompletedNCT03685630Phase 3
• A Study to Test the Safety and Tolerability and Pharmacokinetics of Single Doses of UCB0107 in Healthy Japanese SubjectsCompletedNCT03605082Phase 1
• Named Patient Program With Certolizumab Pegol in Adults Suffering From Rheumatoid Aarthritis (RA)No longer availableNCT03559686
• Compassionate Use Program With Lacosamide in Patients With Partial-onset or Generalized Tonic-clonic SeizuresNo longer availableNCT03559673
• CUP Certolizumab Pegol (CDP-870) in Adults Suffering From Crohn's Disease (CD)No longer availableNCT03559660
• Compassionate Use Program With Brivaracetam for the Treatment of Patients With EpilepsyNo longer availableNCT03532516
• Pharmacokinetic Study Evaluating Staccato® Alprazolam 1 mg Inhaler in Smokers Versus Non-SmokersCompletedNCT03516305Phase 1
• A Study to Assess the Safety and Tolerability of ZX008 in Children and Young Adults With Dravet Syndrome or Lennox Gastaut Syndrome Currently Taking CannabidiolCompletedNCT03467113Phase 1

← UCB S.A. overview and focus areas